Anxiety in Dogs: Comprehensive Welfare Guide

Canine Anxiety and Welfare

Anxiety disorders are among the most prevalent and welfare-significant conditions affecting companion dogs. Affecting an estimated 70%+ of pet dogs in some studies (to varying degrees), anxiety causes chronic suffering, impairs quality of life, and is a major driver of relinquishment and euthanasia. Recognition and treatment are welfare priorities.

Types of Anxiety

• Separation anxiety: Distress when left alone; destructive behaviour, vocalisation, house soiling, and self-trauma when isolated.
• Noise phobia: Fear responses to fireworks, thunder, and other sounds; affects 40-50% of dogs.
• Fear-based aggression: Anxiety-driven aggression toward people, dogs, or specific stimuli; often misidentified as 'dominance'.
• Generalised anxiety disorder (GAD): Chronic, pervasive anxiety across multiple contexts; highly welfare-compromising and often underdiagnosed.
• Social anxiety: Fear of strangers, unfamiliar dogs, or new environments.
• Obsessive-compulsive disorders: Repetitive behaviours (spinning, shadow chasing, flank sucking) often rooted in anxiety or stress.

Welfare Impacts

• Chronic anxiety causes persistent stress hormone elevation with physiological consequences
• Anxious dogs have impaired immune function, increased cardiovascular stress, and reduced lifespan
• Anxiety impairs ability to enjoy normal activities, social interactions, and new experiences
• Untreated anxiety typically worsens over time (sensitisation)
• Anxiety is a major cause of relinquishment — a welfare harm for the dog and owner

Treatment Framework

• Accurate diagnosis: Understanding the specific anxiety type, triggers, severity, and physiological state is essential before treatment.
• Behaviour modification: Systematic desensitisation and counterconditioning (DS/CC) — the gold standard; requires skilled clinical animal behaviourist (APBC/ABTC accredited) guidance.
• Pharmacological support:
  • Daily medication: SSRIs (fluoxetine), TCAs (clomipramine) for generalised or severe anxiety — 4-8 weeks to full effect
  • Situational medication: Trazodone, alprazolam, gabapentin for acute events
  • Sileo (dexmedetomidine) licensed for noise phobia
• Nutraceuticals: Zylkene, Anxitane, Adaptil as complementary support — evidence variable but useful adjuncts.
• Management: Avoiding triggers during treatment; safe haven provision; predictable routines.

Prevention

• Adequate socialisation during the critical period (3-12 weeks)
• Positive, force-free training building confidence and resilience
• Avoiding traumatic experiences, particularly during fear periods
• Providing a secure, predictable home environment

Key Takeaways

Anxiety disorders cause genuine, chronic suffering in millions of dogs. Early recognition, professional behavioural guidance, and appropriate pharmacological support transform welfare outcomes. Anxiety is not 'bad behaviour' — it is a medical condition deserving compassionate, evidence-based treatment.